Portal Diabetes Advances T1D Management with frist Clinical Injections of Portal Insulin and Pump System
Portal Diabetes is making strides in the treatment of Type 1 Diabetes (T1D) with the first clinical injections of Portal Insulin, a key component of its innovative combination system. The company’s CEO, Stacy Chambliss, stated that the Portal Pump is designed to “achieve much better glycaemic control for a dramatically reduced mental burden” for patients [https://www.hospitalmanagement.net/news/portal-diabetes-starts-first-clinical-injections-portal-insulin/].
This milestone marks a meaningful step towards bringing advanced technology to individuals living with T1D. The Portal system aims to simplify insulin delivery and improve blood sugar management, possibly alleviating the daily challenges faced by those managing the condition.
Portal Diabetes is continuing development and anticipates further advancements in its technology to benefit the T1D community.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
[Image of newsletter icon]
Keep reading